ERBB2 and breast carcinoma: Using this immunoPET technique has provided an early insight into the in vivo effect of a new treatment (the heat shock protein-90 [HSP90] inhibitor, AUY922) which down regulates HER2 expression in trastuzumab-refractory breast cancer.